Kiromic BioPharma (KRBP) Welcomes Two New Directors to its Board

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the appointments of Pamela Misajon and Michael Catlin to its Board of Directors. Their regulatory and finance experience enhances Kiromic’s governance and re-establishes the Company’s five-member Board of Directors.

“We are delighted to welcome Pam and Michael to Kiromic’s Board. Pam’s impressive biopharmaceutical experience, including expertise with U.S. and international regulatory strategies, will play a valuable role in advancing our Deltacel program through the clinic. We are confident that her strategic insight and leadership skills will contribute to guiding our development pathway, beginning with non-small cell lung cancer,” stated Michael Nagel, Chairperson of Kiromic’s Board of Directors. “With Michael’s exceptional proficiency in IT and finance, along with his passion for leveraging technology to drive innovation, his appointment aligns with our vision for using our proprietary DIAMOND® AI-powered analysis to continue identifying and developing potential cell therapies to address solid tumor cancers.”

"I am honored to join the Board of Directors at Kiromic Biopharma, a company that is at the forefront of pioneering personalized solid tumor cancer treatments, an area of significant unmet need. I am inspired by the team's dedication to improving patient outcomes through innovative science, and I look forward to contributing my experience and insight to accelerate the development of Kiromic’s Deltacel program," said Ms. Misajon.

"I am passionate about leveraging technology and data-driven approaches to drive innovation in cancer treatments. I look forward to joining the Kiromic Board and contributing to their groundbreaking efforts in precision medicine. As Chair of the Audit Committee and with a keen understanding of the capital markets, I intend to be a resource in responsibly guiding invested capital," said Mr. Catlin.

About Pamela Misajon

Pam Misajon brings to Kiromic more than three decades of experience with a comprehensive background in drug development, regulatory affairs and clinical operations, as well as product commercialization strategies. She has held several high-profile positions within the biopharmaceutical industry, including currently serving as Chief Compliance Officer and Vice President of Operations, Regulatory and Quality Affairs at Suneva Medical.

Prior to Suneva Medical, Ms. Misajon held positions at several pharmaceutical companies, including Vice President of Regulatory Affairs at Neomend, where she played a key role in securing regulatory approvals for multiple breakthrough therapies. She also held executive regulatory and clinical affairs positions at Ellipse Technologies, Pegasus Biologics, and IntraLuminal Therapeutics.

Ms. Misajon received a B.A. in Business Management from the University of Phoenix, San Diego Campus.

About Michael Catlin

As Senior Vice President, Chief Information Security Officer, and Head of Technology Services at Capital Group from 1994 to 2022, Mr. Catlin played a pivotal role in transforming the organization's approach to security. He modernized and expanded the company’s security program, evolving IT to a top business priority. He also had a significant impact on technology infrastructure at Capital Group, overseeing 500 global associates and a $400 million annual budget. His initiatives resulted in improved system availability and streamlined operations to support business growth and effective cost control.

Mr. Catlin serves on Capital Group’s audit committee, the operations risk oversight committee, the information security steering committee, and the American Funds Service board. He is also Chair of the Investment Company Institute.

Mr. Catlin received a B.S. in Business Computer Methods and an M.S. in Computer Science from California State University.

You May Also Be Interested In

• Ainos launches on-site nitrogen generator for AI and chip facilities
• ReElement gets air permits for Indiana rare earth refinery
• Herc Holdings adds former Mobile Mini CEO Erik Olsson to board